Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).The analyst comments "We reviewed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
